Inogen Inc (NASDAQ:INGN) has received a consensus rating of “Buy” from the nine ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $247.33.
A number of research firms recently issued reports on INGN. BidaskClub upgraded shares of Inogen from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 7th. Zacks Investment Research downgraded shares of Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday, September 5th. Piper Jaffray Companies boosted their target price on shares of Inogen to $245.00 and gave the company an “overweight” rating in a research report on Tuesday, August 7th. Stifel Nicolaus set a $258.00 target price on shares of Inogen and gave the company a “buy” rating in a research report on Tuesday, August 21st. Finally, Needham & Company LLC downgraded shares of Inogen from a “strong-buy” rating to a “buy” rating and boosted their target price for the company from $254.00 to $296.00 in a research report on Monday, September 10th.
NASDAQ INGN traded down $2.32 on Monday, reaching $191.98. 475,100 shares of the company’s stock traded hands, compared to its average volume of 233,783. The company has a market capitalization of $4.15 billion, a PE ratio of 146.22, a P/E/G ratio of 3.84 and a beta of 1.56. Inogen has a fifty-two week low of $99.82 and a fifty-two week high of $287.79.
Inogen (NASDAQ:INGN) last posted its earnings results on Tuesday, August 7th. The medical technology company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.21. The company had revenue of $97.24 million during the quarter, compared to the consensus estimate of $81.61 million. Inogen had a net margin of 10.39% and a return on equity of 16.51%. As a group, equities analysts predict that Inogen will post 2.07 earnings per share for the current year.
In other Inogen news, Director Loren L. Mcfarland sold 2,000 shares of the company’s stock in a transaction dated Thursday, August 9th. The shares were sold at an average price of $228.37, for a total value of $456,740.00. Following the completion of the transaction, the director now owns 2,989 shares in the company, valued at $682,597.93. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Byron Myers sold 24,953 shares of the company’s stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $227.13, for a total transaction of $5,667,574.89. Following the completion of the transaction, the executive vice president now owns 42,329 shares of the company’s stock, valued at approximately $9,614,185.77. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,453 shares of company stock valued at $17,125,940. Insiders own 5.29% of the company’s stock.
Institutional investors have recently modified their holdings of the business. Catalyst Capital Advisors LLC acquired a new position in shares of Inogen in the second quarter worth about $112,000. Harvest Fund Management Co. Ltd acquired a new position in shares of Inogen in the third quarter worth about $128,000. Advisory Services Network LLC raised its position in shares of Inogen by 162.5% in the third quarter. Advisory Services Network LLC now owns 525 shares of the medical technology company’s stock worth $128,000 after acquiring an additional 325 shares during the period. First Quadrant L P CA acquired a new position in shares of Inogen in the third quarter worth about $134,000. Finally, Flagship Harbor Advisors LLC raised its position in shares of Inogen by 1,090.9% in the third quarter. Flagship Harbor Advisors LLC now owns 655 shares of the medical technology company’s stock worth $157,000 after acquiring an additional 600 shares during the period. Institutional investors and hedge funds own 96.67% of the company’s stock.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Featured Story: How much money do you need to begin day trading?
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.